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Background: Diabetes mellitus places an enormous burden upon both patients and countries’ health systems. Integral to 
achieving control is patients assuming responsibility for their condition. Self-monitoring of blood glucose (SMBG) can serve as 
a powerful tool modifying lifestyle behaviour and can aid in achieving optimal control.
Methods: This study assessed the effect on diabetes control in patients who received glucometers and education over 12 months. 
This data was analysed at baseline, 6 and 12 months.
Results: Glycaemic control improved significantly between baseline, 6 and 12 months (HbA1c% 12.29  ±  3.17 vs. 11.16  ±  3.09 vs. 
±10.68 ± 3.10, respectively). The number of patients achieving target glycaemic control increased substantially while the number of 
patients achieving target total cholesterol and triglyceride levels improved at six months. Mean HDL cholesterol increased significantly 
between baseline and 12 months (1.20 ± 0.42 vs. 1.31 ± 0.40, respectively; p-value 0.0095). The mean BMI of male patients in the study 
increased between 6 and 121 months (27.59 ± 6.42 vs. 31.90 ± 8.85, respectively, p = 0.0012) and between baseline and 12 months 
(27.64 ± 6.13 vs. 31.90 ± 8.85, respectively, p = 0.0012).
Conclusion: This study demonstrated that the introduction of SMBG and patient education, within this resource-limited clinic 
setting, had beneficial effects on diabetes control; however, obesity remains an obstacle to optimal control.
Keywords: BMI, diabetes control, diabetes mellitus, glycaemic control, obesity, patient education, resource-limited   clinic, 
self-monitoring of blood glucose
Introduction
Diabetes mellitus (DM) is increasing globally.1 Optimal diabetic 
control for most patients has proved elusive in studies in South 
Africa.2−3 Good glycaemic control is vitally important in reducing 
diabetic-related morbidity and mortality.4 Integral to achieving 
optimal diabetic control is empowering the diabetic patient to 
take responsibility for his/her medical condition. Patient 
education is crucial in this process of improving control.
Self-monitoring of blood glucose (SMBG) helps patients make 
informed decisions regarding their dosage of medication and 
helps them decide on whether they need to present urgently to 
their healthcare professional. Self-monitoring can serve as a 
powerful tool for modifying lifestyle behaviour, thereby aiding in 
achieving goals towards optimal control. All diabetic patients 
should ideally have access to their own glucometer but barriers 
to this include limited resources, poverty and unemployment in 
developing countries. A further problem encountered is patient 
anxiety regarding pain associated with finger-prick testing.5
Studies on the benefits of SMBG have been conflicting. Patrick et al.6 
found no definite evidence that home blood glucose monitoring 
improved blood glucose control in his cohort of type 2 diabetic 
patients. However, Guerc et al.,7 in a larger study, showed definite 
evidence that home blood glucose monitoring improved metabolic 
control in diabetic patients. This benefit in controlling blood sugar 
with SMBG was also seen in a later study conducted by McAndrew 
et al.8 Both the DiGEM study9 and the ESMON study10 found no clear 
benefit from SMBG on glycaemic control if SMBG was not 
accompanied by adequate patient education and training with 
regard to the steps to be taken when readings are either high or low 
in respect of medication dosages, exercise and dietary intake.
Our study involved the distribution of glucometers to diabetic 
patients on either insulin monotherapy or a combination of 
insulin and oral antidiabetics, together with extensive patient 
education on the use of the glucometer and directions on what to 
do in the event of hypo- or hyperglycaemia with regard to diet, 
exercise and medication adjustment. Clinical and biochemical 
variables of those patients who received glucometers were 
analysed retrospectively over a one-year period.
Methods
Edendale Hospital is a regional hospital situated in the KwaZulu-
Natal midlands. Accu-chek® glucometers (Roche Diagnostics, 
Switzerland) were donated to the hospital and stored in the 
pharmacy for safekeeping. The diabetic clinic at this hospital started 
issuing these glucometers to all patients on any combination of 
insulin therapy from 1 February 2013. Detailed records of all 
glucometers issued were kept by the pharmacy. On receiving the 
glucometer, the patient returned to the clinic where our diabetic 
nurses/educators trained the patient on their machines. Patients 
were educated on frequency of testing, signs and symptoms of 
hypo- and hyperglycaemia and record keeping of blood glucose 
(BG) readings together with directions on the steps to follow in the 
event of high or low BG reading in terms of medication dose, 
dietary intake and exercise as well as when to report to a healthcare 
institution. All patients on two or more insulin injections per day 
were advised to do SMBG at least three times a day while patients 
on once-daily insulin were advised to do SMBG once daily.
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During the time period when glucometers were handed out, 
transformation of the diabetic clinic was being carried out. A 
multifaceted approach was being employed at the clinic to 
improve diabetes control. This approach targeted both patients 
and the attending clinicians. Extensive patient education was 
being conducted by a fully operational multidisciplinary team 
whilst clinicians were being trained on local SEMDSA diabetes 
guidelines. A comprehensive diabetes datasheet was designed 
and introduced into the clinic to ensure standardisation in the 
approach and management of all diabetic patients.
This study assessed the effect on diabetes control in those 
patients who received glucometers over 12 months. Data on all 
patients who received glucometers from 1 February 2013 to 31 
January 2015 were analysed. This entailed a retrospective chart 
review comparing the following variables in patients who 
received glucometers.
•  At baseline, 6 and 12 months
º  Glycosylated haemoglobin (HbA1c %)
º  Blood pressure (BP): mmHg
º  BMI (kg/m2)
º  Waist circumference (cm)
º  Waist-to-height ratio (WTHR)
º  Total cholesterol and triglycerides (mmol/l)
º  Low-density lipoprotein (LDL) cholesterol and high-density 
lipoprotein (HDL) cholesterol (mmol/l)
º  Glycosuria and proteinuria (using Makromed® urine dipsticks 
from Denmark)
The data collection was approved by the UMgungundlovu Health 
Ethics Review Board (UHERB) and the Biomedical Research Ethics 
Committee (BREC).
Results
A total of 201 patients received glucometers during the study 
period. The majority of these patients had type 2 versus type 1 
DM (142 vs. 59, respectively). Table 1 provides a comparison 
between the demographics of the type 1 and type 2 patients. The 
majority (61.7%) of HIV-infected patients were not on antiretroviral 
therapy.
Table 2 demonstrates the changes noted in the various clinical 
and biochemical variables from baseline to 12 months within the 
entire group of diabetic patients. The mean HbA1c together with 
the number of patients achieving target glycaemic control, total 
cholesterol, triglyceride and LDL cholesterol levels improved 
within the first six months. This positive effect on glycaemic 
control persisted throughout the year following patients receiving 
their glucometers. There was an overall improvement in the HDL 
cholesterol level between baseline and one year. The number of 
patients achieving target blood pressure decreased significantly 
throughout the study period.
When the data were separated further into type 1 and type 2, it 
was noted that the trend of the beneficial effect on mean HbA1c 
and the number of patients achieving target glycaemic control 
persisted in both the type 1 and type 2 diabetic patients (Tables 3 
and 4).
Within the type 2 patient cohort there was a significant 
improvement noted in the first six months in mean triglyceride, 
LDL cholesterol levels, numbers of patients achieving target 
triglyceride levels and the number of patients having urine 
dipstick proteinuria (Table 4).
Discussion
DM is a complicated disease with life-threatening sequelae. 
Control of DM requires a multifaceted approach that includes a 
variety of treatment modalities ranging from patient education to 
a multidisciplinary treatment team, appropriate therapeutics and 
lifestyle changes. A multifaceted approach to diabetes care was 
assessed in a previous study conducted at this resource-limited 
clinic and was found to have beneficial effects on diabetes 
control.19 The implementation of SMBG into our clinic was 
assessed over a two-year period to determine whether the 
addition of SMBG had a positive effect on diabetes control in this 
South African setting.
Only a few diabetic patients in developing countries have access 
to SMBG due to limited resources. Glucometers together with the 
testing strips are expensive so SMBG is a scarce commodity in 
developing countries. According to the latest statistics provided 
by the IDF, 77% of diabetes patients live in low- and middle-
income countries1 while Pillay et al. have shown that the majority 
of patients in the public healthcare sector in KwaZulu-Natal are 
Table 1: Description of patient population
Note: n = number of patients.
Factor Type 1 DM (n = 59) Type 2 DM (n = 142) Total (n = 201)
Gender
 Male 20 36 56 (27.86%)
 Female 39 106 145 (72.14%)
Mean age (years) 34.3 ± 2.09 55.4 ± 0.95 49.17 ± 16.08
Number of patients with HIV infection 22 38 60 (29.85%)
Lifestyle modification
 Diet 42 94 136 (67.66%)
 Exercise 35 63 98 (48.76%)
Number of patients unemployed 54 120 174 (86.57%)
Number of patients with hypertension 22 115 137 (68.16%)
Duration of DM (years) 7.6 ± 8.6 9.8 ± 6.9 9.1 ± 7.5
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diagnosed and have treatment initiated at their local healthcare 
clinics rather than at hospital level.11 Interventions need to be 
implemented to help stem the tide of this diabetic pandemic. 
These interventions need to start at the community level, 
extending through local healthcare clinics and into district and 
regional hospitals. This is where the real need exists and this is 
where any difference made could translate into improvements in 
the entire process. Governments are recognising that non-
communicable diseases (NCDs) need urgent attention to prevent 
the economies of these developing countries being crippled by 
the wave of NCDs. Partnerships need to be brokered between 
pharmaceutical companies and government to ensure diabetic 
patients receive glucometers and testing strips at discounted 
rates. Any improvement in diabetes control with SMBG would 
translate into improved long-term patient outcomes and 
decrease the economic burden for the country as a whole.
Both DM and hyperlipidaemia are regarded as risk factors for 
cardiovascular morbidity and mortality.12−13 We have shown that 
within this cohort of patients who received glucometers, the 
introduction of SMBG in this resource-limited setting had definite 
benefits in improving glycaemic control in the first year. The 
UKPDS study demonstrated that a 1% decrease in HBA1c 
translates into a 37% decrease in micro-vascular complications.4 
Our study showed both a significant drop in HbA1c and an 
increase in the number of patients achieving target glycaemic 
control at both 6 and 12 months. This improvement in glycaemic 
control was coupled to a decrease in the number of patients with 
urine dipstick findings of glycosuria. At six months, there was a 
definite improvement in the number of patients achieving target 
total cholesterol, triglyceride and LDL cholesterol levels. Although 
there was an improvement in mean LDL cholesterol levels, these 
levels were still well above the recommended level of 1.8 mmol/l.14 
The majority of patients (73.13%) were on statin therapy. This 
statin therapy was optimised based on the lipogram results 
during the study. The mean HDL level increased substantially 
between baseline and 12  months. This is promising as the 
Framingham study noted that HDL cholesterol was a protective 
factor in coronary artery disease (CAD)20 while Gordon et al. 
demonstrated a 2–3% decrease in CAD risk for every 10% decrease 
Table 2: Changes in clinical and biochemical characteristics from baseline to 12 months for combined type 1 and type 2 patients










 Systolic BP (mmHg) 131.30 ± 24.60 131.40 ± 22.80 133.50 ± 25.10 0.9464 [2] 0.4018 [2] 0.3814 [2]
 Diastolic BP (mmHg) 79.60 ± 13.80 79.40 ± 14.40 80.60 ± 13.90 0.8666 [2] 0.4109 [2] 0.4984 [2]
Number of patients with 
BP ≤ 140/80 mmHg 95 93 71 0.8159 [1] 0.0084 [1] 0.0151 [1]
Mean HbA1c, % 12.29 ± 3.17 11.16 ± 3.09 10.68 ± 3.10 0.0003 [2] 0.1278 [2] < 0.0001 [2]
Number of patients with 
HbA1c ≤ 7, % 9 28 40 0.0012 [1] 0.0835 [1] < 0.0001 [1]
Mean total cholesterol 
(mmol/l) 4.58 ± 1.28 4.39 ± 1.27 4.35 ± 1.28 0.1657 [2] 0.8237 [2] 0.1118 [2]
Mean triglyceride 
(mmol/l) 1.96 ± 1.31 1.86 ± 1.66 1.81 ± 1.13 0.5184 [2] 0.7733 [2] 0.2642 [2]
Mean HDL cholesterol 
(mmol/l) 1.20 ± 0.42 1.24 ± 0.37 1.31 ± 0.40 0.2712 [2] 0.1149 [2] 0.0095 [2]
Mean LDL cholesterol 
(mmol/l) 2.45 ± 1.08 2.19 ± 0.95 2.36 ± 1.14 0.0548 [2] 0.1736 [2] 0.5610 [2]
Number of patients with:
 Total cholesterol  
< 4.5 mmol/l 94 113 105 0.0545 [1] 0.7405 [1] 0.1160 [1]
 Triglyceride  
< 1.7 mmol/l 87 107 94 0.0422 [1] 0.2998 [1] 0.3255 [1]
Mean waist circumference 
(cm) 104.74 ± 16.96 102.77 ± 19.22 103.99 ± 16.51 0.2960 [2] 0.4496 [2] 0.6744 [2]
Mean BMI (kg/m2)
 Males 27.64 ± 6.13 27.59 ± 6.42 31.90 ± 8.85 0.9706 [2] 0.0012 [2] 0.0012 [2]
 Females 33.81 ± 7.45 34.04 ± 7.56 33.78 ± 9.13 0.8069 [2] 0.8021 [2] 0.9693 [2]
Number of patients with 
WTHR < 0.5 17 22 18 0.3488 [1] 0.6444 [1] 0.6466 [1]
Number of patients with:
 Glycosuria 103 80 92 0.0289 [1] 0.0391 [1] 0.9483 [1]
 Proteinuria 26 28 22 0.5548 [1] 0.5330 [1] 0.8374 [1]
*[1] Chi-square; [2] Student’s t-test.
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circumferences (≥ 86  cm in males and  ≥  92  cm in females)17 as 
indicators of obesity, this study showed that the prevalence of 
obesity in our female patients remained high throughout the 
study. Male patients, however, showed a significant trend towards 
developing obesity during the study. This can possibly be 
attributed to unhealthy eating choices often associated with 
poverty, as the majority of our patients were unemployed, or 
increased doses of insulin therapy. A WTHR of > 0.5 is an excellent 
indicator of obesity and adverse cardiovascular outcomes.18 Only 
a minority of the study patients managed to achieve the target 
WTHR of  <  0.5, again emphasising the problem of the global 
obesity pandemic.
Our study showed definite benefit in those patients performing 
SMBG. The diabetic patients at resource-limited healthcare clinics 
could benefit from receiving glucometers together with 
appropriate education on its use.
Now that the roll-out of glucometers is well on its way in the clinic, 
the next phase of this process is to introduce a computer installed 
with the appropriate software to upload SMBG readings from the 
glucometer into the clinic’s database and have it printed for the 
in HDL cholesterol level.21 The increased trend in obesity and 
unhealthy eating habits could possibly be related to the low 
numbers of patients achieving lipid control.
The UKPDS study found that control of blood pressure in diabetic 
patients was essential in preventing long-term diabetes 
complications.4 Our patients demonstrated neither a substantial 
improvement, nor worsening of their overall blood pressures; 
however, there was a significant decrease in the number of patients 
achieving target blood pressures at the one-year mark. Part of our 
multifaceted approach to diabetes care entailed reviewing the 
patients’ blood pressures and optimising their antihypertensive 
medications. This is a worrying trend and more emphasis needs to 
be placed on attaining optimal blood pressure control as outlined 
by local hypertension guidelines. The high prevalence of obesity 
together with worsening of BMI noticed in male patients within 
this cohort could possibly explain this phenomenon.
Globally obesity remains a constant obstacle to the development 
of and successful management of DM.1,15 South African women 
have the highest prevalence of obesity in sub-Saharan Africa.16 
Using either a body mass index of ≥ 30 kg/m2 or increased waist 
Table 3: Changes in clinical and biochemical characteristics from baseline to 12 months within the type 1 DM cohort










 Systolic BP (mmHg) 121.2 ± 17.9 124.0 ± 21.1 125.3 ± 20.4 0.4549 [2] 0.7445 [2] 0.2749 [2]
 Diastolic BP (mmHg) 75.6 ± 12.2 76.3 ± 13.4 79.6 ± 13.2 0.7691 [2] 0.2047 [2] 0.1066 [2]
Number of patients 
with BP  
≤ 140/80 mmHg
32 32 25 1.000 [1] 0.5298 [1] 0.5298 [1]
Mean HbA1c, % 12.57 ± 3.68 11.26 ± 3.64 10.97 ± 3.77 0.0575 [2] 0.6834 [2] 0.0245 [2]
Number of patients 
with HbA1c ≤ 7, % 3 12 13 0.0093 [1] 0.7407 [1] 0.0038 [1]
Mean total cholesterol 
(mmol/l) 4.42 ± 1.22 4.36 ± 1.66 4.41 ± 1.69 0.8161 [2] 0.8629 [2] 0.9739 [2]
Mean triglyceride 
(mmol/l) 1.44 ± 0.96 1.79 ± 2.57 1.31 ± 0.85 0.3710 [2] 0.2111 [2] 0.4625 [2]
Mean HDL cholesterol 
(mmol/l) 1.25 ± 0.40 1.29 ± 0.36 1.35 ± 0.37 0.5532 [2] 0.4742 [2] 0.1951 [2]
Mean LDL cholesterol 
(mmol/l) 2.58 ± 1.31 2.40 ± 1.17 2.42 ± 1.17 0.5937 [2] 0.9298 [2] 0.6352 [2]
Number of patients with:
 Total cholesterol  
< 4.5 mmol/l 29 32 31 0.5385 [1] 0.9394 [1] 0.5919 [1]
 Triglyceride  
< 1.7 mmol/l 35 39 35 0.4518 [1] 0.4518 [1] 1.0000 [1]
Mean waist circumfer-
ence (cm) 94.29 ± 15.49 90.90 ± 18.70 94.66 ± 16.74 0.3064 [2] 0.2920 [2] 0.9092 [2]
Mean BMI (kg/m2)
 Males 25.32 ± 6.07 26.04 ± 6.62 25.64 ± 6.10 0.7277 [2] 0.8501 [2] 0.8782 [2]
 Females 30.22 ± 6.58 30.36 ± 6.49 29.43 ± 6.54 0.9257 [2] 0.5598 [2] 0.6217 [2]
Number of patients 
with WTHR < 0.5 10 13 9 0.5451 [1] 0.6216 [1] 0.9300 [1]
Number of patients with:
 Glycosuria 29 25 28 0.5071 [1] 0.2430 [1] 0.5962 [1]
*[1] Chi-square; [2] Student’s t-test.
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clinician. This will ensure that the clinician makes an informed 
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Future studies will evaluate the impact of this in the clinic.
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